Skip to content
Review Open access

T-cell engagers in solid tumors: challenges and emerging strategies

Nov 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 144 references

TL;DR

The structural and mechanistic foundations of TCE activity are examined, including antibody fragment–based constructs, IgG-like bispecific antibodies, T-cell receptor–based engagers, and emerging multispecific platforms, which are positioning TCEs as an increasingly adaptable and durable therapeutic platform for solid tumors.

Abstract

T-cell engagers (TCEs) redirect endogenous T cells toward malignant cells by simultaneously binding a tumor-associated target and a T-cell receptor component, most commonly CD3, thereby inducing immune-synapse formation and cytotoxicity independently of conventional antigen recognition. Although TCEs have transformed the treatment of several hematologic malignancies, their development in solid tumors remain limited by heterogeneous and non–tumor-specific antigen expression, impaired tumor penetration and T-cell trafficking, an immunosuppressive tumor microenvironment, and immune-mediated toxicities. This review examines the structural and mechanistic foundations of TCE activity, including antibody fragment–based constructs, IgG-like bispecific antibodies, T-cell receptor–based engagers, and emerging multispecific platforms. We discuss how molecular size, valency, geometry, epitope location, binding affinity, and pharmacokinetic engineering influence immune-synapse quality, antitumor potency, cytokine release, tissue distribution. Major barrier efficacy, including on-target, off-tumor toxicity, antigen heterogeneity and escape, restricted T-cell infiltration, T-cell exhaustion, and metabolic and immunologic suppression are critically evaluated. The evolving clinical landscape across major solid tumors is reviewed, with emphasis on tebentafusp in metastatic uveal melanoma and tarlatamab in previously treated small-cell lung cancer, illustrating the importance of aligning target biology, molecular format, and dosing strategy. We also address cytokine release syndrome, neurologic toxicity, resistance, and treatment failure and highlight strategies designed to widen the therapeutic window and sustain antitumor activity, including step-up dosing, affinity and avidity tuning, conditional or protease-activated constructs, dual-target and trispecific platforms, localized or genetically encoded delivery, rational combinations, and predictive biomarkers. Together, these advances are positioning TCEs as an increasingly adaptable and durable therapeutic platform for solid tumors.

Read PDF

Similar papers

Open access

Exploring the immunotherapeutic potential of Vγ9Vδ2-T cells in cancer using bispecific antibodies

Bispecific T cell engagers (bsTCEs) are engineered antibodies designed to simultaneously bind a tumor-associated antigen (TAA) and, most commonly, the CD3 complex on T cells. By bridging tumor and effector cells, bsTCEs promote the formation of an immunological synapse that triggers potent cytotoxic responses, bypassin...

Milon de Jong · 0 citations
Review Open access Oct 2026

NK-Cell Engagers in Cancer Immunotherapy: Recent Advances, Translational Challenges, and Future Strategies

Priorities include matching engager design to tumor and effector biology, optimizing pharmacokinetic and pharmacodynamic properties, defining predictive biomarkers, and developing rational combinations that translate early responses into durable disease control.

Jennifer D. Wu · 0 citations
Open access Oct 2026

Local T-cell engager secretion reprograms endogenous antitumor immunity and enhances CAR-T cell persistence in solid tumors

Background Adoptive T-cell therapies can mediate potent antitumor activity, yet their efficacy against solid tumors remains limited by antigen heterogeneity, tumor escape, and insufficient induction of endogenous antitumor immunity. Whether distinct T cell-redirecting strategies differentially engage host immune respon...

Javier Arroyo-Ródenas, Alex Chen, Jason M. Tonne et al. · 0 citations
Open access Nov 2026

T cell-mediated antibody-dependent cellular cytotoxicity provides a therapeutic approach for solid cancers.

The clinical success of chimeric antigen receptor T cells in treating hematological malignancies has highlighted the immense therapeutic potential of engineering T cells with synthetic receptors. However, the limited availability of tumor-specific antigens and the poor ability of T cells to infiltrate solid tumor cores...

Alon Richter, S. Dotan, Petr Shendrik et al. · 0 citations
Open access Oct 2026

T cell engagers convert acute tumor killing into endogenous vaccination

T cell engagers (TCEs) redirect T cells to kill tumors by cross-linking CD3ε to a tumor antigen, independently of T cell receptor specificity. Some patients achieve remissions that persist long after drug clearance, but whether TCEs can couple acute cytotoxicity to the generation of lasting adaptive immunity remains un...

Mathilde M. Lecuit, B. Corre, Z. Garcia et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.